Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
NCT00380276 · Myrexis Inc. · PHASE3 · terminated · last registry update 2008-08-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Myriad has discontinued the development of Flurizan.” | – | Registry record, Myrexis Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against APH1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision